Combination of HMG-CoA reductase inhibitors atorvastatin or simvastatin with a phosphodiesterase 4 inhibitor such as roflumilast for the treatment of inflammatory pulmonary diseases
WOLLIN, STEFAN-LUTZ,WOHLSEN, ANDREA,MARX, DEGENHARD,BRAUN, CLEMENS
申请号：
DK11164518
公开号：
DK2363130T3
申请日:
2007.07.03
申请国别(地区):
DK
年份:
2014
代理人:
摘要：
The invention relates to the combined use of a PDE4 inhibitor with a HMG-CoA reductase inhibitor for the preventive and curative treatment of an inflammatory pulmonary disease, wherein the PDE4 inhibitor is selected from the group consisting of ROFLUMILAST, a pharmaceutically acceptable salt of ROFLUMILAST, ROFLUMILAST-N-oxide and a pharmaceutically acceptable salt of ROFLUMILAST-N-oxide, the HMG-CoA reductase inhibitor is ROSUVASTATIN or a pharmaceutically acceptable salt thereof.
